Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Neuroimmunomodulation. 2013;20(2):113-8. doi: 10.1159/000345994. Epub 2013 Jan 10.
Neuromyelitis optica (NMO) and multiple sclerosis (MS) are two autoimmune inflammatory demyelinating diseases in the central nervous system. Interleukin (IL)-6 and IL-17 may play important roles in the pathogenesis of these diseases. High-mobility group box protein 1 (HMGB1) can activate the nuclear factor light chain enhancer of activated B cells and release cytokines such as IL-6 and IL-17. However, whether cerebrospinal fluid (CSF) HMGB1 levels were altered in NMO and MS patients is still unclear.
It was our aim to measure the CSF HMGB1 concentration in NMO patients and explore their relationship with IL-6, IL-17 and disease activity.
CSF HMGB1 was measured by enzyme-linked immunosorbent assay in NMO (n = 22) and MS (n = 18) patients as well as in controls (n = 14).
CSF HMGB1 was notably higher in the NMO group compared with controls (p = 0.007). CSF HMGB1 positively correlated with IL-6 and IL-17 in NMO patients (IL-6, p = 0.034; IL-17, p < 0.001).
In conclusion, our study suggests that CSF levels of HMGB1 are increased in patients with NMO and reflect the neuroinflammatory process.
视神经脊髓炎（NMO）和多发性硬化（MS）是两种中枢神经系统自身免疫性炎症性脱髓鞘疾病。白细胞介素（IL）-6 和 IL-17 可能在这些疾病的发病机制中发挥重要作用。高迁移率族蛋白 B1（HMGB1）可激活核因子 B 细胞激活物的轻链增强子并释放如 IL-6 和 IL-17 等细胞因子。然而，NMO 和 MS 患者脑脊液（CSF）HMGB1 水平是否改变仍不清楚。
我们旨在测量 NMO 患者的 CSF HMGB1 浓度并探讨其与 IL-6、IL-17 和疾病活动的关系。
通过酶联免疫吸附试验（ELISA）测量 NMO（n = 22）、MS（n = 18）患者和对照组（n = 14）的 CSF HMGB1。
NMO 组的 CSF HMGB1 明显高于对照组（p = 0.007）。NMO 患者的 CSF HMGB1 与 IL-6 和 IL-17 呈正相关（IL-6，p = 0.034；IL-17，p < 0.001）。
总之，我们的研究表明，NMO 患者的 CSF 中 HMGB1 水平升高，反映了神经炎症过程。
